Penny Stock Investors may want to take a closer look at CytoSorbents Corp. (CTSO) after Wall Street analysts, Brean Murray, initiated coverage on them Tuesday. Using blood purification to treat life-threatening illnesses, the critical care focused therapeutic device company was issued a “buy” rating and a $0.50 price target, a possible 317% gain. Currently, CTSO stock price is 0.1199, up 3.36%, with volume of 327,503 as of mid-day.
Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE.
CTSO Stock Chart
Market Cap: $22,604,513 a/o Jul 23, 2012
Shares Outstanding: 194,866,495
Price/Sales (ttm): 426.73
Price/Book (mrq): 38.67
20 Day Percent Change: -3.33%
20 Day Moving Average: 0.1193
20 Day Average Volume: 453,761
Roughly 3 weeks ago, CytoSorbents announced promising large animal data from a research collaboration with Dr. David Rabkin, Assistant Professor of Surgery, Division of Cardiothoracic Surgery at the University of Washington Medical Center in Seattle, Washington. In a presentation on June 29th entitled “Effect of Cytokine Hemoadsorption on Brain Death Induced Ventricular Dysfunction in a Porcine Model” at the Annual Meeting of the Western Thoracic Surgical Association in Hawaii, Dr. Rabkin was scheduled to present animal data supporting the potential future use of CytoSorb® blood purification to protect the viability of organs donated by patients whose organs still function, but who have been declared officially dead from irreversible brain injury.
To Review the Most recent SEC filings for CTSO, click here.
About CTSO Stock
Cytosorbents Corp. is a critical care focused therapeutic medical device company that is currently in the development stage. The Company has developed and is seeking to commercialize a blood purification technology that is believed to be able to efficiently remove middle molecular weight toxins from circulating blood and physiologic fluids. In March 2011, the Company received European Union (E.U.) regulatory approval under the CE Mark and Medical Devices Directive for their flagship product, CytoSorb®, as an extracorporeal cytokine filter to be used in clinical situations where cytokines are elevated. The CE Mark enables CytoSorb® to be sold within the European Union for clinical use.
Bottom Line: After the recent passing of Obamacare, penny stocks in the medical device field have not seen as much attention as expected. CTSO is generating revenues, although small, and has a very interesting product with their CytoSorb®, preserving organs for transplantation from persons declared legally deceased or with irreversible brain damage.
Here is your opportunity to subscribe to the Most Exclusive Penny Stock newsletter.
Sign up with your email address now & get ready to make BIG PROFITS on Hot Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share